number – Asia Tab

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

24 11 月, 2022

TOKYO, Nov 24, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.Key data Presentations for perampanel include the:- Results from a post hoc analysis of the phase III clinical trial (FREEDOM/342), which evaluated long-term efficacy of perampanel monotherapy by seizure type in the open-label extension (52 weeks) for epilepsy patients with focal-onset seizures (FOS), ≥ 12 years of age without prior treatment history (poster number: 2.228)- Real-world pooled analyses of perampanel for pediatric patients (poster number: 1.310),adolescent patients (poster number: 1.313) and elderly patients (poster number: 1.312)- Results from a post hoc analysis of two phase III open-label extension (OLEx) studies, Study 307 and Study 335 OLEx, evaluating the long-term efficacy and safety of adjunctive perampanel in a subgroup of older adult patients aged ≥ 60 years (poster number: 1.291)"With 34 poster presentations planned for this year's AES Meeting, we look forward to furthering our understanding of the results that may impact overall care in epilepsy," said Ivan Cheung, Senior Vice President Global Alzheimer's Disease Officer President, Americas Region, Eisai Co., Ltd., "We remain focused on addressing the diverse needs of patients with epilepsy and their families."Perampanel is a first-in-class AED discovered by Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper- excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. The agent is currently approved for partial-onset seizures (with or without secondarily generalized seizures) in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. The agent is currently approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, and other countries in Europe and in Asia.Eisai considers neurology, including epilepsy, a therapeutic area of focus. Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their familiesFor more information, visit www.eisai.com/news/2022/pdf/enews202281pdf.pdf. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Gotion High-tech: GDRs listing has been approved by China Securities Regulatory Commission

24 7 月, 2022

HONG KONG, Jul 24, 2022 - (ACN Newswire via SEAPRWire.com) - Gotion High-tech Co., Ltd. ("Gotion High-tech" or the "Company") announced on the evening of July 22 that the Company recently received the "Approval for Gotion High-tech Co., Ltd.'s initial public offering of Global Depositary Receipts and listing on the SIX Swiss Exchange AG" issued by the China Securities Regulatory Commission ("CSRC"). As approved by CSRC, the total number of A shares of the Company represented by the Global Depositary Receipts (hereinafter referred to as "GDRs") to be offered may not exceed 249,706,175. According to the conversion ratio determined by the Company, the total number of GDRs to be offered by the Company may not exceed 49,941,235. If the conversion ratio is adjusted, the number of GDRs issued can be adjusted accordingly. Following the completion of this offering, the Company can be listed on the SIX Swiss Exchange AG. The upper limit of the number of GDRs under the duration of the Company's GDRs is consistent with the actual size of the GDRs issuance. If the GDRs increases or decreases due to the Company's bonus policy, share split or merger, or adjustment of the conversion ratio, the upper limit of the number of GDRs shall be adjusted accordingly.Gotion High-tech has disclosed for the first time on March 16 that the Company proposes to issue GDRs overseas and list on the SIX Swiss Exchange AG. The proceeds of GDRs raised will be mainly used to support the expansion of the Company's business, particularly to grow its overseas production capacity of battery products and raw materials through investment in fixed assets, acquisition of equity interests or other means, to increase the Company's international footprint. As a world-leading and rapidly expanding provider of new energy solutions, Gotion High-tech has reached strategic cooperation with a number of international customers and signed product sales orders, and plans to increase the production capacity of EV batteries and supplementary components in overseas markets such as Europe, North America, and Asia. The Company believes that this GDRs issuance will help it to expand the global market share of its products, promote the diversification of shareholder structure, and continue to boost the steady development of the Company. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)